Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could your sleep quality predict Alzheimer's? new study investigates racial differences

NCT ID NCT03814603

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed observational study looked at whether poor sleep quality, specifically slow wave sleep, is linked to brain changes that raise Alzheimer's risk, and whether this link differs between African-American and white older adults. Researchers recruited 210 cognitively normal adults aged 60-75, monitored their sleep at home and in a lab, and used brain scans to measure amyloid plaques, a hallmark of Alzheimer's. The goal was to understand why African-Americans have higher Alzheimer's rates, not to test any treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help explain why African-Americans have a higher risk of Alzheimer's, pointing to sleep as a key factor for future prevention strategies.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all populations or lead to direct interventions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

210 people

The number who actually took part.

Started

Nov 2018

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

210 cognitively normal elderly (Clinical Dementia Rating \[CDR\]=0), self-identified as African-American (AA) or non-Hispanic white (NHW), ages 60 to 75 years, with English as their primary language

Ages

60 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female subjects with normal cognition and ages 60 to 75. * Within normal limits on neurological and psychiatric examinations. All subjects enrolled will have a CDR=0. * An informed family member or life-partner (preferably bed-partner) will be interviewed over the phone or on the first or second visit to confirm the reliability of the subject interview. A study partner is preferably a spouse, close friend, or relative. * Self-identified as African-American Black or non-Hispanic white. * All subjects must sign the Alzheimer's Disease Center consent form Exclusion Criteria: * History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders). * Significant history of alcoholism based off of the CAGE questionnaire (\>2) or drug abuse. * History of psychiatric illness (e.g., schizophrenia, bipolar or PTSD) * Lifelong depression and anxiety will be allowed as long as there has been no active depressive episode within the last two years. * Geriatric Depression Scale (short form)\>6. * Insulin dependent diabetes. * Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions based off of the PI's discretion. * Physical impairment of such severity as to adversely affect the validity of psychological testing. * Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging. * Medications affecting cognition or SWS: * Narcotic analgesics. * Chronic use of medications with anticholinergic activity. * Anti-Parkinsonian medications (carbidopa/levodopa, amantadine, bromocriptine, pergolide, selegiline). * Others: amphetamines, amphetamine-like compounds, appetite suppressants, phenothiazines, reserpine, buspirone, clonidine, disulfiram, guanethidine, MAO inhibitors, theophylline, tricyclic antidepressants, gabapentin, pregabalin, trazodone, cholinesterase inhibitors, memantine. * Chronic use of antidepressants are allowed. * History of a first-degree family member with early onset (age \<60 years) dementia. * Short sleepers (\< 5 hours a day) and long sleepers (\> 10 hours a day). * OSA (defined as AHI4%\>15 and AHI4%\>5 with Epworth≥10) * Self-identified as US-born Caribbean Black, Caribbean-born Black or African-born Black.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NYU Center for Brain Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.